This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (63)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Evidence-Based Medicine  • Alert me on articles by topic

David Moher, MSc

JAMA. 1998;279:1489-1491.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORTS OF RANDOMIZED controlled trials (RCTs) have become the "gold standard" by which health care professionals make decisions about the effectiveness of most interventions. Such reports, accurately documenting the conduct of RCTs, should be of the highest possible quality to ensure that their results are as free of bias as possible. Proposals to help improve the quality of reports of RCTs have existed for some time.^1-2 Unfortunately, the evidence indicates that there is still considerable room for improvement in how RCTs are reported.

Pocock and colleagues³ reported that a statement about sample size was mentioned in only 5 (11.1%) of 45 reports and that only 6 (13.3%) made use of confidence intervals. These investigators also noted that the statistical analysis tended to exaggerate intervention efficacy because authors reported a higher proportion of statistically significant results in their abstracts compared with the body of the papers. Altman and . . . [Full Text of this Article]

From the Departments of Pediatrics, Medicine, and Epidemiology and Community Medicine, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa.

RELATED ARTICLE

Beyond CONSORT: Need for Improved Reporting Standards for Clinical Trials
Curtis L. Meinert
JAMA. 1998;279(18):1487-1489.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health
Cranney et al.
Am. J. Clin. Nutr. 2008;88:513S-519S.
ABSTRACT | FULL TEXT  

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
Fountzilas et al.
Ann Oncol 2008;19:853-860.
ABSTRACT | FULL TEXT  

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
Vandenbroucke et al.
ANN INTERN MED 2007;147:W-163-W-194.
ABSTRACT | FULL TEXT  

Commentary: Strengthening the reporting of observational epidemiology the STROBE statement
Egger et al.
Int J Epidemiol 2007;0:dym199v1-dym199.
FULL TEXT  

Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
Fountzilas et al.
Ann Oncol 2006;17:1560-1567.
ABSTRACT | FULL TEXT  

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Fountzilas et al.
Ann Oncol 2005;16:1762-1771.
ABSTRACT | FULL TEXT  

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
Fountzilas et al.
Ann Oncol 2004;15:1517-1526.
ABSTRACT | FULL TEXT  

Clinical Trials in the Journal of Pediatric Psychology: Applying the CONSORT Statement
Stinson et al.
J Pediatr Psychol 2003;28:159-167.
ABSTRACT | FULL TEXT  

Policy, the Public, and Priorities in Alternative Medicine Research
JONAS
The ANNALS of the American Academy of Political and Social Science 2002;583:29-43.
ABSTRACT  

Value of Flow Diagrams in Reports of Randomized Controlled Trials
Egger et al.
JAMA 2001;285:1996-1999.
ABSTRACT | FULL TEXT  

CONSORT Revised--Improving the Reporting of Randomized Trials
Rennie
JAMA 2001;285:2006-2007.
FULL TEXT  

Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group
Fountzilas et al.
JCO 2001;19:2232-2239.
ABSTRACT | FULL TEXT  

Electronic Trial Banks: A Complementary Method for Reporting Randomized Trials
Sim et al.
Med Decis Making 2000;20:440-450.
ABSTRACT  

A Scale of Methodological Quality for Clinical Studies of Radiologic Examinations
Arrivé et al.
Radiology 2000;217:69-74.
ABSTRACT | FULL TEXT  

Measuring the Quality of Trials: The Quality of Quality Scales
Berlin and Rennie
JAMA 1999;282:1083-1085.
FULL TEXT  

Impact of Formal Continuing Medical Education: Do Conferences, Workshops, Rounds, and Other Traditional Continuing Education Activities Change Physician Behavior or Health Care Outcomes?
Davis et al.
JAMA 1999;282:867-874.
ABSTRACT | FULL TEXT  

The CONSORT Statement: Will It Lead to Improved Reporting of Clinical Trials in Ophthalmology?
Hawkins
Arch Ophthalmol 1999;117:677-680.
FULL TEXT